ICT Partners with Lyell Immunopharma in Landmark Deal for Solid Tumor CAR-T Therapy LYL273

Dec 14, 2025 22:00 CST Updated 22:00

ICT

Oncology Drug Developer

Lyell Immunopharma

Cell Therapy New Drug Developer

Haoyue Values

MissionEmpower with Capital, Achieve Excellence in Healthcare Enterprises

VisionTo become the most outstanding investment bank in China's healthcare industry

HaoYue Capital was founded in January 2014 and is a leading investment bank in China focused on the healthcare industry. The company's headquarters is located in Shanghai, with regional offices in Beijing, Shenzhen, Hong Kong, and Singapore. HaoYue Capital is committed to supporting China's outstanding healthcare companies in successfully accessing the capital markets through capital assistance and research-driven insights, creating added value for clients. HaoYue Capital consistently tracks the dynamics and investment trends of the healthcare investment market, with research and transaction coverage spanning multiple sub-sectors including innovative pharmaceuticals, innovative medical devices, IVD and life sciences, health services, and smart healthcare. As of 2024, HaoYue Capital has completedHundreds ofProject. Over the past decade, HAOYUE Capital has deeply engaged in private equity financing, mergers and acquisitions, and complex transactions of listed companies, maintaining a comprehensive leading position in various sub-sectors of the healthcare industry.